Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial
Martin A Katzman et al. Int Clin Psychopharmacol. 2011 Jan.
Abstract
The objective of this study was to evaluate the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) as maintenance monotherapy for patients with generalized anxiety disorder (GAD). Time-to-event (anxiety symptom recurrence; maximum 52 weeks) multicenter, randomized-withdrawal, parallel-group, double-blind, placebo-controlled study of quetiapine XR (50-300 mg/day) following open-label run-in (4-8 weeks) and open-label stabilization (≥ 12 weeks). Primary variable: time from randomization to anxiety event. Secondary variables included: Hamilton Anxiety Rating Scale (HAM-A) total, HAM-A psychic/somatic anxiety factors, Clinical Global Impression-Severity of Illness (CGI-S), and Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) scores; adverse events (AE) reporting. Four hundred and thirty-two patients, stabilized on quetiapine XR, were randomized to continue quetiapine XR (N=216) or switch to placebo (N=216). Risk of anxiety symptom recurrence was significantly reduced by 81% for quetiapine XR versus placebo: hazard ratio=0.19 (95% confidence interval 0.12-0.31; P<0.001). Fewer patients receiving quetiapine XR (N=22, 10.2%) than placebo (N=84, 38.9%) experienced anxiety symptom recurrence. Significant differences were observed between quetiapine XR and placebo in: HAM-A total, psychic/somatic, CGI-S (all P<0.001) and Q-LES-Q (P<0.05) scores. AEs (>10%) during open-label treatment were dry mouth, sedation, somnolence, dizziness, fatigue, and constipation. During randomized treatment, the most common AEs for quetiapine XR were headache and nasopharyngitis. Quetiapine XR monotherapy reduced the risk of anxiety symptom recurrence in patients with GAD stabilized on quetiapine XR, with tolerability results consistent with the known profile of quetiapine.
Similar articles
- Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Liebowitz M, et al. Depress Anxiety. 2010 Oct;27(10):964-76. doi: 10.1002/da.20740. Depress Anxiety. 2010. PMID: 20734365 Clinical Trial. - A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.
Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. Khan A, et al. J Clin Psychopharmacol. 2011 Aug;31(4):418-28. doi: 10.1097/JCP.0b013e318224864d. J Clin Psychopharmacol. 2011. PMID: 21694613 Clinical Trial. - Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.
Merideth C, Cutler AJ, She F, Eriksson H. Merideth C, et al. Int Clin Psychopharmacol. 2012 Jan;27(1):40-54. doi: 10.1097/YIC.0b013e32834d9f49. Int Clin Psychopharmacol. 2012. PMID: 22045039 Clinical Trial. - Quetiapine: a review of its use in the management of bipolar depression.
Sanford M, Keating GM. Sanford M, et al. CNS Drugs. 2012 May 1;26(5):435-60. doi: 10.2165/11203840-000000000-00000. CNS Drugs. 2012. PMID: 22519923 Review. - Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Figueroa C, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):199-204. doi: 10.1016/j.pnpbp.2008.09.026. Epub 2008 Oct 9. Prog Neuropsychopharmacol Biol Psychiatry. 2009. PMID: 18948162 Review.
Cited by
- Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.
IsHak WW, Meyer A, Freire L, Totlani J, Murphy N, Renteria S, Salem M, Chang T, Abdelsalam R, Khan R, Chandy T, Parrish T, Hirsch D, Patel B, Steiner AJ, Kim S, Hedrick R, Pechnick RN, Danovitch I. IsHak WW, et al. Innov Clin Neurosci. 2024 Sep 1;21(7-9):27-47. eCollection 2024 Jul-Sep. Innov Clin Neurosci. 2024. PMID: 39329027 Free PMC article. Review. - Post-therapy plasma concentrations of quetiapine in Taiwanese patients.
Huang CY, Lin YF, Chen CR, Lin SK. Huang CY, et al. Neuropsychopharmacol Rep. 2023 Mar;43(1):50-56. doi: 10.1002/npr2.12303. Epub 2023 Jan 16. Neuropsychopharmacol Rep. 2023. PMID: 36647121 Free PMC article. - Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.
Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, Remington G, Siskind D, Agarwal SM, Hahn MK. Stogios N, et al. Neuropsychopharmacology. 2022 Feb;47(3):664-672. doi: 10.1038/s41386-021-01163-7. Epub 2021 Aug 26. Neuropsychopharmacology. 2022. PMID: 34446830 Free PMC article. - Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment.
Xu Y, Amdanee N, Zhang X. Xu Y, et al. CNS Drugs. 2021 Dec;35(12):1265-1274. doi: 10.1007/s40263-021-00859-0. Epub 2021 Aug 24. CNS Drugs. 2021. PMID: 34427901 Review. - The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders.
Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A. Pignon B, et al. Curr Psychiatry Rep. 2017 Nov 7;19(12):103. doi: 10.1007/s11920-017-0847-x. Curr Psychiatry Rep. 2017. PMID: 29110139 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical